In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies (Q46982839)

27 December 2017

title

In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies (English)

1 reference

27 December 2017

1 reference

G Montiel-Manzano

1

1 reference

27 December 2017

Z Romay-Penabad

2

1 reference

27 December 2017

E Papalardo de Martínez

3

1 reference

27 December 2017

L A Meillon-García

4

1 reference

27 December 2017

E García-Latorre

5

1 reference

27 December 2017

E Reyes-Maldonado

6

1 reference

27 December 2017

S S Pierangeli

7

1 reference

27 December 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

27 December 2017

Annals of the New York Academy of Sciences

published in

1 reference

27 December 2017

volume

1108

1 reference

27 December 2017

page(s)

540-553

1 reference

27 December 2017

Antiphospholipid syndrome: antibodies and antigens

cites work

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

The tissue factor pathway in disseminated intravascular coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

Multiple nuclear factors interact with the immunoglobulin enhancer sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

NF-kappaB activation plays a role in superoxide-mediated cerebral endothelial dysfunction after hypoxia/reoxygenation

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

NF-kappaB signaling: pros and cons of altering NF-kappaB as a therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

The NF-kappa B and I kappa B proteins: new discoveries and insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

Inhibition of the proteasome reduces transfer-induced diabetes in nonobese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

NF-kappaB and inflammation in genetic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

Inhibition of tumor growth by NF-kappaB inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

E-Selectin mediates pathogenic effects of antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

Pathophysiology of the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.057

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1422.057

1 reference

27 December 2017

1 reference

27 December 2017